| Indication | Drug Discovery |
Preclinical | Clinical Phase 1 |
Clinical Phase 2 |
Clinical Phase 3 |
Release |
|---|---|---|---|---|---|---|
| Obesity | ||||||
| Diabetes |
| Code | Indication | Drug Discovery |
Preclinical | Clinical Study |
Marketing Authorization |
Release |
|---|---|---|---|---|---|---|
| DKF-MA102 | Prostate cancer | |||||
| DKF-MB101 | Immuosuppression | |||||
| DKF-MA201 | Growth Hormone | |||||
| DKF-MB201 | Growth Hormone | |||||
| DKF-313 | Prostatic Hypertrophy | |||||
| DKF-335 | Osteoporosis | |||||
| DKF-460 | Dyslipidemia |
| Code | Indication | Drug Discovery | Preclinical | Clinical Study | Marketing Authorization | Release |
|---|---|---|---|---|---|---|
| DKM-428 | Skin protection | |||||
| DKB-119 | Tissue repair (Filler) | |||||
| DKB-133 | Tissue repair (Filler) |